Abstract:This study aimed to explore the pharmacokinetic features of levofloxacin (LVFX) in Chinese patients with infections and to confirm oral LVFX 500 mg once daily as an optimal treatment regimen based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. A total of 1052 plasma samples from 164 Chinese adult patients with communityacquired lower respiratory tract infections (CALRTIs) and 18 healthy volunteers were used for population PK analysis. LVFX 500-mg tablets were given once daily. A nonlinear mixed effects model (NONMEM) program was used for population PK model-building and a two-compartment model with first-order absorption process was established. Creatinine clearance (CL cr ) and body weight were identified as intrinsic factors which significantly affected oral clearance (CL t /F) and the apparent volume of distribution of the central compartment (V1/F), respectively. The final model is described as follows: CL t /F (l/h) = (8.97 + 0.917 × (CL cr (ml/min) − 100.92) × 60/1000) × exp (η CLt/F ). V1/F (l) = (85.3 + 1.22 × (weight (kg) − 60.75)) × exp (η V1/F ). Q/F (l/h) = 0.351. V2/F (l) = 6.81. k a (h −1 ) = 1.44 × exp(η ka ). Based on the population PK model, mean C max and AUC 0–24h in CALRTI patients were estimated as 5.13 µg/ml and 58.98 µg·h/ml, respectively. A subgroup analysis showed that patients with mild renal dysfunction (50 ml/min ≤ CL cr < 80 ml/min) had 34% higher AUC 0–24h values compared to patients with normal renal function (CL cr ≥ 80 ml/min). Postmodeling simulation using final population PK estimates also showed that C max and AUC 0–24h increased markedly in patients with severe renal dysfunction. The results indicate that LVFX dosage adjustment should be individualized on the basis of the CL cr , especially in those with CL cr less than 50 ml/min. None of the PK parameters had any correlation with the occurrence of adverse events. PK-PD analysis indicated that, in patients treated with LVFX 500 mg once daily, the AUC 0–24h /MIC ratio exceeded the target for those major CALRTI pathogens isolated. In addition, the C max /MIC ratio reached 5 for Streptococcus pneumoniae , indicating that the emergence of LVFX-resistant S. pneumoniae could be prevented during the therapy with this dosage regimen. These results demonstrate that oral LVFX 500 mg once daily has favorable PK parameters and PK-PD features in patients with CALRTIs, and the results strongly support this dosage regimen for the treatment of CALRTI.

Population pharmacokinetics of cefixime in Chinese healthy male subjects

Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body

Pharmacokinetics and Bioequivalence Study of Cefixime Tablet in Healthy Volunteers

Establish the Population Pharmacokinetics Model of Azithromycin in Chinese Healthy Volunteers

Population Pharmacokinetics of Ambroxol Hydrochloride in Chinese Healthy Male Subjects

Physiologically Based Pharmacokinetic Modeling of Cefadroxil in Mouse, Rat, and Human to Predict Concentration–Time Profile at Infected Tissue

Population pharmacokinetics of citalopram by NONMEM

Pharmacokinetics of Multiple-Dose Cefazedone Sodium in Chinese Healthy Subjects

Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions

Clinical pharmacokinetics of gemifloxacin following single oral dose administration in healthy Chinese male subjects

Population Pharmacokinetics Of Zonisamide After Oral Administration In Healthy Chinese Volunteers

Population Pharmacokinetics of Moxifloxacin and Its Concentration–qt Interval Relationship Modeling in Chinese Healthy Volunteers

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers

Study on Clinical Pharmacokinetics and Pharmacodynamics of Cefprozil

Using Monte Carlo Simulation to Determine Optimal Dosing Regimen for Cefetamet Sodium for Injection

Physiologically Based Pharmacokinetic Model of Renally Cleared Antibacterial Drugs in Chinese Renal Impairment Patients.

[Population Pharmacokinetics of Ciprofloxacin in Chinese Elderly Patients with Lower Respiratory Tract Infection].

Population Pharmacokinetics of Vancomycin and Prediction of Pharmacodynamics in the Chinese People

Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients

Population Pharmacokinetics of Oral Levofloxacin 500mg Once-Daily Dosage in Community-Acquired Lower Respiratory Tract Infections: Results of a Prospective Multicenter Study in China